Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research 3: Modification of Radiation Sensitivity

Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine

Hideaki Dote, David Cerna, William E. Burgan, Donna J. Carter, Michael A. Cerra, Melinda G. Hollingshead, Kevin Camphausen and Philip J. Tofilon
Hideaki Dote
NIH/NCI, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Cerna
NIH/NCI, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William E. Burgan
NIH/NCI, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna J. Carter
NIH/NCI, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Cerra
NIH/NCI, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melinda G. Hollingshead
NIH/NCI, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Camphausen
NIH/NCI, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip J. Tofilon
NIH/NCI, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

1222

Aberrant DNA hypermethylation is a frequent finding in tumor cells, which suggested that inhibition of DNA methylation may be an effective cancer treatment strategy. Because DNA methylation affects gene expression and chromatin structure, parameters considered to influence radioresponse, we investigated the effects of the DNA methylation inhibitor zebularine on the radiosensitivity of human tumor cells. Three human tumor cell lines were used in this study (MiaPaCa, DU145 and U251) and the methylation status of three genes frequently hypermethylated in tumor cells (RASSF1A, HIC-1 and 14-3-3 σ) was determined as a function of zebularine exposure using methylation specific PCR and reverse-transcription PCR. Zebularine resulted in DNA demethylation in a time dependent manner, with the maximum loss of methylation detected by 48h. To determine whether zebularine enhances radiosensitivity, cell lines were exposed to zebularine for 24 or 48 h before irradiation and performance of the colony-forming efficiency assay. Exposure to zebularine for 24 h before irradiation resulted in an increase in radiosensitivity of each cell line with DEFs (dose enhancement factors at a surviving fraction of 0.1) of 1.25, 1.15 and 1.24 for MiaPaCa, DU145 and U251, respectively. Zebularine treatment alone resulted in surviving fractions of 0.93 ± 0.095, 0.66 ± 0.093 and 0.65 ± 0.068 for MiaPaCa, DU145 and U251, respectively. When the cell lines were exposed to zebularine for 48 h before irradiation there was a greater degree of enhancement of radiation-induced cell killing with DEFs of 1.51, 1.67 and 1.59 for MiaPaCa, DU145 and U251, respectively. Using this protocol the surviving fractions for zebularine exposure alone were 0.35 ± 0.066, 0.22 ± 0.038 and 0.42 ± 0.041 for MiaPaCa, DU145 and U251, respectively. As a measure of radiation-induced DNA damage, γH2AX expression was determined. Whereas zebularine had no effect on radiation-induced γH2AX foci at 1 h, the number of γH2AX foci per cell was significantly greater in the zebularine-treated cells at 24 h after irradiation suggesting the presence of unrepaired DNA damage. These in vitro studies were then extended to an in vivo xenografts model. Zebularine administration to mice reactivated gene expression in U251 xenografts; irradiation of U251 tumors in mice treated with zebularine resulted in an increase in radiation-induced tumor growth delay. These results indicate that zebularine can enhance tumor cell radiosensitivity in vitro and in vivo and suggest that this effect may involve an inhibition of DNA repair.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine
Hideaki Dote, David Cerna, William E. Burgan, Donna J. Carter, Michael A. Cerra, Melinda G. Hollingshead, Kevin Camphausen and Philip J. Tofilon
Cancer Res May 1 2005 (65) (9 Supplement) 284;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine
Hideaki Dote, David Cerna, William E. Burgan, Donna J. Carter, Michael A. Cerra, Melinda G. Hollingshead, Kevin Camphausen and Philip J. Tofilon
Cancer Res May 1 2005 (65) (9 Supplement) 284;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The novel thrombopoietic agent AMG 531 is effective in pre-clinical models of chemo/radiotherapy induced thrombocytopenia
  • When prostate brachytherapy fails; a case report and discussion
  • Radiation dose and risk of second malignant neoplasms after cancer in childhood: A nested case-control study
Show more Clinical Research 3: Modification of Radiation Sensitivity
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement